DISEASE & TREATMENT SETTING
VOTRIENT: advanced Soft tissue sarcoma after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.2 Soft Tissue Sarcoma VOTRIENT is indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
Broader topic: Soft Tissue Sarcoma
- Source population
- Not part of this definition
- Disease extent
- advanced
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- who have received prior chemotherapy
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for VOTRIENT (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.2 Soft Tissue Sarcoma VOTRIENT is indicated for the treatment of adults with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice
Triangle